Friedrich Graf Finckenstein
Overview
Explore the profile of Friedrich Graf Finckenstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
5370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schoenfeld A, Lee S, Doger de Speville B, Gettinger S, Hafliger S, Sukari A, et al.
Cancer Discov
. 2024 Apr;
14(8):1389-1402.
PMID: 38563600
In this phase 2 multicenter study, we evaluated the efficacy and safety of lifileucel (LN-145), an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non-small cell lung cancer (mNSCLC)...
2.
Chesney J, Lewis K, Kluger H, Hamid O, Whitman E, Thomas S, et al.
J Immunother Cancer
. 2023 Jan;
10(12).
PMID: 36600653
Background: Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response...
3.
Sarnaik A, Hamid O, Khushalani N, Lewis K, Medina T, Kluger H, et al.
J Clin Oncol
. 2021 May;
39(24):2656-2666.
PMID: 33979178
Purpose: Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes has...
4.
Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, et al.
Clin Cancer Res
. 2017 Sep;
23(18):5394-5405.
PMID: 28916617
Nivolumab is a fully human IgG4 monoclonal antiprogrammed death-1 antibody with demonstrated efficacy, including durable responses and prolonged survival, in patients with previously treated, advanced non-small cell lung cancer (NSCLC)....
5.
Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, et al.
N Engl J Med
. 2015 Sep;
373(17):1627-39.
PMID: 26412456
Background: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. Methods: In this randomized, open-label, international phase 3 study, we...
6.
Hou X, Huang F, Macedo L, Harrington S, Reeves K, Greer A, et al.
Cancer Res
. 2011 Nov;
71(24):7597-607.
PMID: 22042792
Insulin-like growth factor (IGF) signaling has been implicated in the resistance to hormonal therapy in breast cancer. Using a model of postmenopausal, estrogen-dependent breast cancer, we investigated the antitumor effects...
7.
Huang F, Hurlburt W, Greer A, Reeves K, Hillerman S, Chang H, et al.
Cancer Res
. 2010 Sep;
70(18):7221-31.
PMID: 20807811
Agents targeting insulin-like growth factor-I receptor (IGF-IR), including antibodies and small-molecule inhibitors, are currently in clinical development for the treatment of cancers including sarcoma. However, development of resistance is a...
8.
Guarino M, Schneider C, Hosford M, Brahmer J, Rudin C, Graf Finckenstein F, et al.
Oncologist
. 2009 Feb;
14(2):119-24.
PMID: 19182243
Purpose: To determine the optimal dose of the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab that can be safely administered in combination with a standard daily dose of erlotinib...
9.
Davicioni E, Anderson M, Graf Finckenstein F, Lynch J, Qualman S, Shimada H, et al.
Am J Pathol
. 2009 Jan;
174(2):550-64.
PMID: 19147825
Rhabdomyosarcoma (RMS) in children occurs as two major histological subtypes, embryonal (ERMS) and alveolar (ARMS). ERMS is associated with an 11p15.5 loss of heterozygosity (LOH) and may be confused with...
10.
Ren Y, Graf Finckenstein F, Abdueva D, Shahbazian V, Chung B, Weinberg K, et al.
Cancer Res
. 2008 Aug;
68(16):6587-97.
PMID: 18701482
Alveolar rhabdomyosarcomas (ARMS) are highly malignant soft-tissue sarcomas that arise in children, adolescents, and young adults. Although formation and expression of the PAX-FKHR fusion genes is thought to be the...